CST, 57411S, LPCAT1 (E4V4B) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying LPCAT1. Validated for Western Blotting,Immunoprecipitation,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, LPCAT1 (E4V4B) Rabbit Monoclonal Antibody (CST #57411) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Immunohistochemistry (Paraffin): 1:2000 - 1:8000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 81677 . Protocol Available protocols: Western Blotting, Immunoprecipitation, Immunohistochemistry (Paraffin) Specificity / Sensitivity LPCAT1 (E4V4B) Rabbit Monoclonal Antibody recognizes endogenous levels of total LPCAT1 protein. Non-specific staining was observed in pancreas by immunohistochemistry. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala524 of human LPCAT1 protein. Background LPCAT1 (lysophosphatidylcholine acyltransferase 1), an enzyme that functions in phospholipid metabolism and remodeling, has been reported to be highly expressed and to play a tumor-promoting role in multiple human cancers. Overexpression of LPCAT1 is linked to poor prognosis in breast cancer and hepatocellular carcinoma (HCC) (1,2). In cervical cancer, knockdown of LPCAT1 reduces proliferation, migration, and invasion of cancer cells, and LPCAT1 deletion reduces tumor growth and metastasis in mice through Jak2/Stat3 signaling (3). In endometrial cancer, LPCAT1 enhances stemness and metastasis through TGF-β signaling (4). In non-small cell lung cancer (NSCLC), LPCAT1 upregulates EGFR/PI3K/Akt signaling, promoting resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) (5). Due to its high expression in cancer, as well as its role in tumor promotion and drug resistance, LPCAT1 is a potential therapeutic target and prognostic biomarker. Alternate Names 1-acylglycerol-3-phosphate O-acyltransferase; 1-acylglycerophosphocholine O-acyltransferase; 1-alkenylglycerophosphocholine O-acyltransferase; 1-alkylglycerophosphocholine O-acetyltransferase; Acetyl-CoA:lyso-PAF acetyltransferase; Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; acyl-CoA:lysophosphatidylcholine acyltransferase 1; acyltransferase like 2; Acyltransferase-like 2; AGPAT10; AGPAT9; AYTL2; FLJ12443; FLJ41609; LPC acyltransferase 1; lpcat; LPCAT-1; LPCAT1; Lyso-PAF acetyltransferase; LysoPAFAT; LysoPC acyltransferase 1; Lysophosphatidylcholine acyltransferase 1; PCAT1; PFAAP3; Phosphonoformate immuno-associated protein 3; regulated by phosphonoformate Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 55 Source/Isotype: Rabbit IgG